AstraZeneca’s Imfinzi Approved by FDA for Bladder Cancer Treatment
The US Food and Drug Administration (FDA) has approved AstraZeneca’s (NASDAQ: AZN) PD-L1 inhibitor Imfinzi...
MicroPort Endovascular Reports 1.61% Revenue Growth in 2024 with Strong Profit Increase
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) released its 2024 financial report, showing a...
Luye Pharma Group Reports 2024 Revenue Dip Despite Growth in Product Sales
China-based Luye Pharma Group (HKG: 2186) announced its 2024 financial performance, recording RMB 6.061 billion...
Hengrui Pharmaceuticals Reports 22.63% Revenue Growth in 2024 with Strong Innovative Drug Sales
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) released its 2024 financial report, recording RMB...
Sanofi’s Qfitlia Approved by FDA for Hemophilia A and B Prophylaxis
France-based Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving marketing approval from the US Food...
Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting
China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase...
Akeso Biopharma Reports 53% Revenue Decline in 2024 Despite Growth in Product Sales
China-based Akeso Biopharma (HKG: 9926) released its 2024 financial report, recording RMB 2.124 billion (USD...
IASO Biotherapeutics’ Fucaso Approved in Macao for Relapsed Multiple Myeloma
China-based IASO Biotherapeutics announced that the New Drug Application (NDA) for its BCMA-targeted chimeric antigen...
Eli Lilly Launches Kisunla in China for Early Alzheimer’s Treatment
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has officially launched Kisunla (donanemab) in...
Laekna Submits Revised Protocol for LAE102 Obesity Trial with Eli Lilly
Sino-US biotech Laekna Therapeutics (HKG: 2105) announced the submission of a revised clinical protocol to...
Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment
Apollomics Inc. announced on March 31, 2025, a strategic development and commercialization agreement with Taiwan-based...
Bioray Biopharmaceutical Expands to Turkey with Three Key Drugs, Marking International Milestone
Zhejiang Bioray Biopharmaceutical Co., Ltd. announced on March 31 that it has reached a collaboration...
EClinCloud Secures New Funding to Accelerate AI Innovation in Clinical Research
EClinCloud (Ningbo) Technology Co., Ltd., a leading AI technology company specializing in clinical research solutions,...
China Tightens Medical Device Quality Oversight: 2025 Inspection Plan Unveiled
China’s National Medical Products Administration (NMPA) has released its 2025 medical device inspection plan, outlining...
Policy Analysis: Shanghai’s 2025 Pharmaceutical Procurement Regulation and Market Implications
Shanghai’s Medical Centralized Bidding and Procurement Affairs Management Office has released its January 2025 list...
Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics
The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized...
China Unveils 2025 Medical Device Inspection Strategy to Tighten Quality Control
China’s National Medical Products Administration (NMPA) convened a pivotal conference in Chengdu on March 24...
Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma
Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton...
Sinovac Biotech’s SNA02-48 Gains Clinical Approval for Tetanus Prevention
Beijing Sinovac Biotech Co., Ltd’s (NASDAQ: SVA) subsidiary Sinovac Life Sciences Co., Ltd. and its...
Shanghai Designates Backup Suppliers and Specialized Drug Formulations in GY-YD2024-2 Procurement
Shanghai has finalized its list of second-tier backup suppliers and manufacturers for specialized drug formulations...